Not a financial Adviser. Everything is my opinion only
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another fantastic Quarterly by MRMD
Impressive numbers
https://www.globenewswire.com/news-release/2022/05/10/2440180/0/en/MariMed-Reports-First-Quarter-2022-Earnings.html
LOL
How about this clown. Dont Buy a single share and kick rocks
Stop wasting my time.
2022 Guidance $150M with an additional $120M-$210M EST additional Rev from growth & acquisitions.
Present MCAP $199M
LOL
Market just turned today with the FOMC meeting. Gonna be a fun ride up
If your not buying at these levels I cant help you
Q1 earnings coming soon. Care to guess how many millions of dollars of product MRMD is selling.
Put this nonsense to bed once and for all
Again with the BostonGlobe?
Look at the financials and stop falling for click bait articles that you said you didn't even bother to read.
You really should proof read your own copy and paste articles. This one opinion piece only proves my point. Taxes are the reason the government will protect the interest of the large companies and people are consuming cannabis way more than alcohol regardless of the price.
Earlier this week, Massachusetts announced that, for the first time, cannabis tax revenue in that state exceeded tax revenue from alcohol sales. Midway through the 2021-2022 fiscal year, Massachusetts rang up $74 million in cannabis excise taxes, compared to $51 million in alcohol excise taxes.
People are shifting away from alcohol and using cannabis more,” said Pat Gottschlicht, a co-founder of INSA Cannabis, a Massachusetts-based cannabis company that’s expanding to Florida and Pennsylvania. “This is a sign that the East Coast industry is catching up.”
Nobody cares Gio. California has crazy taxes for everything.
Read the financials and stop posting nonsense articles.
Business is booming and will be even bigger with a recession and multiple new locations/Licenses.
This is a $10 stock in 1-2 years
Maybe management heard some people here clearly and decided to drop the 2022 plan a bit
off schedule and maybe trap a couple criminals in the process
Either way business is growing
In IQSTs defense this is the best 10K this company has ever put out and possible the best 10K from any OTC company in 2021. If this is arguable please enlighten us.
Present me a company with less shares outstanding, Less A/S, better revenue, more cash on hand, better margins, better Y/Y growth, smaller MCAP, less debt, less convertible shares, more acquisitions in the pipeline, better management, more international reach, more business divisions and less dilution.
Not sure what people were expecting did you want them to acquire Verizon?
We all read what kind of revenue the Smart tank brings in. One more large contract could add over 100M easy if not more...it is an award winning product for a reason. 3 target acquisitions incoming. Global one, EVOSS! Please, your shares will be acquired by smart money. Announcing selling shares 3 days before you do should be looked at with great skepticism regardless.
Hello Maryland Cultivation / Production license and 100 more Medical dispensaries
MariMed Receives Maryland State Approval for
Transfer of Ownership of Kind Therapeutics USA
NORWOOD, Mass., April 14, 2022 — MariMed Inc. (OTCQX: MRMD) (“MariMed” or the “Company”), a leading multi-state cannabis operator focused on improving lives every day, today announced that the Maryland Medical Cannabis Commission (MMCC) has approved the transfer of 100% of the ownership of Kind Therapeutics U.S.A., LLC (“Kind”), a leading vertically integrated cannabis business to MariMed Inc.
The approval was granted during the MMCC’s Full Commission Meeting on Wednesday, April 13, 2022. The parties will now move forward to complete the closing of the transactions previously announced. Upon closing, Kind will become a wholly owned subsidiary of MariMed and its financials will be consolidated with MariMed’s in the Company’s public filings.
Kind operates under its cannabis cultivation and production licenses in its Hagerstown, MD manufacturing plant. It is completing development of a dispensary in Anne Arundel County under its provisional dispensary license. Kind’s cannabis products, including MariMed brands, are distributed to the approximately 100 medical dispensaries in the Maryland medical cannabis program. Maryland’s medical cannabis program has more than 139,000 registered patients and, according to the MMCC, the state receives more than 200 applications for medical cannabis cards every day. Maryland’s medical cannabis program generated more than $500 million in sales in 2021. According to Cowen Research, with a population of 6.2 million, Maryland’s medical cannabis program boasts some of the highest rates of registered medical consumers, incidence usage and spending, on a per capita basis, among all legal medical cannabis programs in the United States. The state legislature recently approved a November 2022 ballot referendum for voters to approve an adult use cannabis program.
About MariMed
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies, Nature’s Heritage, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations: High + Energy. For additional information, visit www.marimedinc.com.
LOL... Getting weird in here.
I tell ya what, If I dont like a company I move on...Just me?
32M revenue - MCAP 9M
XDSL anticipates generating several different revenue streams from EV charging station operators, retailers and consumers. Management believes its platform contains the broadest software content of any EV charging company currently providing services and believes this will provide a key competitive advantage.
XDSL is building on a strong existing revenue base; the company has a roughly $32 million in existing annual revenue. Revenue from new growth initiatives is expected to come on stream beginning in FY 2023. As the company introduces new services, technologies and products, XDSL expects consolidated revenue to transition to a higher margin mix over time.
Speaking of SEC
Certainly anybody here has an interest in the company. Including your employer. Tread carefully
In Gary Genslers words help keep the market free from "bad actors"
If you see any post that may be seen as an attempt at stock manipulation feel free to contact the SEC whistleblower program. Most times these "bad actors" have a position or are working with someone who has a short position in a company or would otherwise benefit from making up inaccurate posts.
https://www.sec.gov/whistleblower
You'd be surprised how active the SEC has become on cleaning things up.
Reach out if you feel you see any Nefarious activities in XDSL or any other company you follow.
They will take it from their
Here is a recent example how social media can be used illegally:
SEC Wins Jury Trial: Hedge Fund Adviser Found Liable for Securities Fraud
FOR IMMEDIATE RELEASE
2021-224
Washington D.C., Nov. 5, 2021 —
Jurors in Boston federal court today returned a verdict in the Securities Exchange Commission’s favor against a hedge fund adviser and his investment advisory firm.
Gregory Lemelson and Massachusetts-based Lemelson Capital Management LLC were charged with fraud in September 2018 for reaping more than $1.3 million in illegal profits by making false statements to drive down the price of San Diego-based Ligand Pharmaceuticals Inc. The SEC’s evidence at trial showed that after establishing a short position in Ligand through his hedge fund, Lemelson made a series of false statements to shake investor confidence in Ligand and lower its stock price, increasing the value of his fund’s position. The false statements included assertions that Ligand’s investor relations firm had agreed that Ligand’s most profitable drug was on the brink of obsolescence and that Ligand had entered into a sham transaction with an unaudited shell company in order to pad its balance sheet. The evidence also showed that Lemelson had boasted about bringing down Ligand’s stock price through his “multi-month battle” against the company.
The jury found Lemelson and Lemelson Capital Management liable for fraudulent misrepresentations. The court will determine remedies at a later date.
“Investment professionals play a crucial role in our markets and when they break the law they undermine investors’ trust,” said Gurbir S. Grewal, Director of the SEC’s Division of Enforcement. “We’ll continue to use all of the tools in our toolkit to hold wrongdoers accountable, including litigating whenever necessary. This verdict underscores that commitment as well as our staff’s ability, tenacity, and experience to win those trials.”
Recession looming. Geopolitical and economic fears. Retail and institutions are risk off at the present time. Everything is getting clobbered. Bonds, stocks, crypto, commodities. Record high inflation.
Blood in the streets you buy and hold the gems.
One needs nothing more than to read the latest financials to see where this is eventually headed once the fears dissipate.
This is longterm.
Or you can get your stock picks from the Boston globe.....hehe. Cant even type that with a straight face
LOL....So you didn't even read the article that you posted twice.
Did you read the financials? Just kidding I dont care....
Boston globe hahahahaha
MRMD doesn't care either, especially about the Boston globe news rag.... neither do actual customers
2022 FINANCIAL TARGETS
Considering MariMed’s strategic plan to drive long-term growth, recent acquisitions, license wins, and current industry dynamics, the Company has set the following financial targets for the full fiscal year 2022:
Revenue of $145 to 150 million.
Adjusted EBITDA of $47 to $52 million.
CAPEX spend of approximately $25 million
“After setting financial targets in 2021 for the first time, and subsequently raising and beating them, I am pleased to announce very strong financial growth targets for 2022,” said Jon Levine, Chief Financial Officer of MariMed. “Our strict financial discipline combined with our outstanding operations give us confidence we will meet or beat our full year financial guidance once again in 2022.”
2022 FINANCIAL TARGETS
Considering MariMed’s strategic plan to drive long-term growth, recent acquisitions, license wins, and current industry dynamics, the Company has set the following financial targets for the full fiscal year 2022:
Revenue of $145 to 150 million.
Adjusted EBITDA of $47 to $52 million.
CAPEX spend of approximately $25 million
“After setting financial targets in 2021 for the first time, and subsequently raising and beating them, I am pleased to announce very strong financial growth targets for 2022,” said Jon Levine, Chief Financial Officer of MariMed. “Our strict financial discipline combined with our outstanding operations give us confidence we will meet or beat our full year financial guidance once again in 2022.”
These guys are multi state award winning edibles. LOL But but the Boston globe says weed stinks... HAhahahahahahah
Subsequent to the end of the 2021 fiscal year, the Company announced several significant business developments, including:
A definitive agreement to acquire Kind Therapeutics USA, LLC(“Kind”) a leading vertically integrated cannabis operation in Maryland that the Company developed and has managed for several years. Kind leases and operates its cultivation and production licensed businesses in a 180,000 square foot industrial building owned by the Company in Hagerstown and will lease and operate its provisional dispensary license in a building owned by the Company in Annapolis.
A definitive agreement to acquire a craft cannabis license in Illinois that will enable MariMed to become fully vertical in that high-growth state. The Company will soon begin construction of a new cultivation and processing facility in Mount Vernon, Illinois. When completed, the Company expects to sell its portfolio of award-winning brands in its four Thrive dispensaries and into the Illinois wholesale cannabis marketplace. The Company expects this will lead to higher revenue and gross margins from operations in Illinois
A definitive agreement to acquire a provisional dispensary license for an adult-use dispensary in a high-traffic location in Beverly, Massachusetts. When opened, this will be the Company’s second adult-use dispensary in the state, further increasing Company revenue and margins and brand recognition in Massachusetts. strengthening branded product distribution and increasing margins over time.
The launch of its new Vibations: High + Energy drink mix, marking the Company’s entry into the fast-growing cannabis beverage category. This innovative, all-natural drink mix is made from full spectrum cannabis and provides focus and energy for the mind and body. Vibations: High + Energy is available at select dispensaries in Massachusetts, including MariMed’s Panacea Wellness in Middleborough. The brand will soon also be available in Delaware and Maryland.
The continued strong financial performance in the fourth quarter of 2021 was driven by:
Revenue from retail dispensary operations grew 89% during the fourth quarter, and 177% for the full year 2021, compared to the same periods from the prior year. Revenue growth was driven by a new dispensary in Metropolis, IL, and higher customer visits in both Illinois and Massachusetts.
Revenue from wholesale sales of cannabis flower, concentrates, and infused products grew 5% during the fourth quarter, and 151% for the full year 2021, compared to the same periods from the prior year. This was a result of both the increased production of MariMed’s manufacturing facility in Massachusetts and the increased number of licensed dispensary clients in the state.
The Company launched Bubby’s Baked, its new line of THC-infused baked goods, in December 2021 in Massachusetts. The launch of Bubby’s Baked was supported by a robust sales and marketing plan which included baking the world’s largest THC-infused brownie. Weighing 850 pounds and infused with 20,000 milligrams of THC, the brownie garnered the Company and the product line global attention, generating nearly five billion consumer impressions.
Boston globe...hahahaha
Their just like any other BS news source these days. You fell for that click bait headline?
Try reading a financial. Thats were the truth is.
FOURTH QUARTER AND FULL YEAR FINANCIAL HIGHLIGHTS
Fourth quarter revenue of $31.0 million and full year revenue of $121.5 million, an increase of 52% and 139%, respectively, compared to the same periods from the prior year.
Fourth quarter gross profit of $15.5 million and full year gross profit of $66.3 million, an increase of 33% and 112%, respectively, compared to the same periods from the prior year.
Fourth quarter Adjusted EBITDA* of $8.3 million and full year Adjusted EBITDA of $43.1 million, a change of –7% and 144%, respectively, compared to the same periods from the prior year.
Working capital at December 31, 2021 of $17.4 million compared to a working capital deficit of $2.2 million at December 31, 2020.
Fourth quarter cash flow provided by operations of $7.9 million and full year cash flow provided by operations of $35.9 million, an increase of 347% and 961%, respectively, compared to the same periods from the prior year
Share price 2/01/21 was .35
3 week later 2/21/21 it hit $2.00
And IQST is a much much better company now....so Im not worried
How's everybody doin?!! Looking good here gentlemen. LFG!!
People might want to wake up on how undervalued MRMD is.
Finna miss out
Bullish divergence
Everything is coming together nicely
IQST
They just announced that an undervalued company is now even more undervalued. I do not see a nearly doubling of guidance as bad news.
$90M for 2022 with intentions to add an additional $80 million to that forecast through the other arms of business seems like good news to me considering the MCAP is sitting at $68M at the moment.
I believe this figure is fluid as most of these deals are constantly being negotiated throughout many subsidiaries. So I wouldn't expect a response until deals are done. Keep in mind it could be more. Last years guidance was beat so they have a history of overdelivering on revenue forecast.
Unfortunately we are in one of the ugliest pullbacks the market has seen in quite some time but this magnifies the significance of finding solid undervalued companies. Even large caps right now are moving like penny stocks. AAPL is down 16% YTD....ever heard of them? TSLA down 28%. FB down 44%. AARK down 60% yearly. I could go on and on. Almost every stock is down some as much as 80%. Blue chip, Dow, Nasdaq, MidCap, large cap, Crypto, good news, earnings beat.....it doesn't matter. Any company with a high multiple is getting gut checked right now.
With all things considered we are holding up pretty good here.
IQST has been doing work, making deals, winning awards and paying off debt in a responsible matter.
I believe the shorts know this thing can rip anytime now and are not willing to risk it. Clearly the bulls know it as well and are holding their shares with both hooves.
Good stuff Knux
I want to point out IQST went from a low of $.59 Dec 23rd to a high of $1.05 Dec 31.....In a span of 6 trading days. With the same share structure.
When its ready it moves fast. Another smart tank contract, another acquisition, profitable Q1....etc can send this sailing.
I believe the overall market has bottomed and we might see buyers stepping in in March
Completely agree on the selective lending partners. The sharks have been swirling these OTC waters for decades and sometimes cleverly disguised. IQST new management has done very well navigating these waters and Im in agreement to let funding and uplist take as long as it needs.
With everything discussed, revenue projections and filings, Leandro and team has shown shareholders they have a solid grasp on growing this company in many different directions....one of those being ethically.
IQST
Article on what most OTC companies are up against
https://www.thebasilelawfirm.com/post/microcap-terrorism-a-warning-to-otc-ceo-s
Article on the DOJ investigation on what retail investors have been pounding the table about for years:
https://www.reuters.com/world/us/us-prosecutors-explore-racketeering-charges-short-seller-probe-sources-2022-02-18/
I dont know what your "con" is. But I have an idea
Jeez..That PR wasn't even put out by IQST. They were simply mentioned in it.
Last PR they released was:
We achieved an estimated $6.7 million in revenue in January, which is a 42% increase over the $4.8 million in revenue we realized in January 2021. Forecasted $90 million in 2022
In January, iQSTEL also received The Smart Appliance Product of the Year Award from IoT Breakthrough for its IoTSmartTank device.
January also saw iQSTEL reach a notable milestone as it formally entered the electric vehicle (EV) market place with its first EVs rolling off the production line.
These three substantial milestones in the first month of the year - double digit revenue growth, a technology award, and EV market entry - are strong positive indicators of what lies ahead for iQSTEL in 2022 and, I believe, representative of iQSTEL's Nasdaq worthy caliber.
Jeez..That PR wasn't even put out by IQST. They were simply mentioned in it.
Last PR they released was:
We achieved an estimated $6.7 million in revenue in January, which is a 42% increase over the $4.8 million in revenue we realized in January 2021. Forecasted $90 million in 2022
In January, iQSTEL also received The Smart Appliance Product of the Year Award from IoT Breakthrough for its IoTSmartTank device.
January also saw iQSTEL reach a notable milestone as it formally entered the electric vehicle (EV) market place with its first EVs rolling off the production line.
These three substantial milestones in the first month of the year - double digit revenue growth, a technology award, and EV market entry - are strong positive indicators of what lies ahead for iQSTEL in 2022 and, I believe, representative of iQSTEL's Nasdaq worthy caliber.
Is this too fluffy for you?
Nice run into the close. Still only about $4 undervalued